The Journal of Informed Pharmacotherapy 2000;1:402.
Troy F. Cook, B.Sc.(Pharm), Peter J.
Zed, B.Sc.(Pharm), Pharm.D. James R. Busser, MD, FRCPC, MHSc., Lyne
Filiatrault, MD, FRCPC, FACEP
CSU Pharmaceutical Sciences and CSU Emergency Medicine, Vancouver Hospital & Health Sciences Centre and the Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Canadian Society of Hospital Pharmacists (British Columbia Branch) Residency Research Presentation Night (Podium and Poster presentation). Vancouver, British Columbia, Canada. May 10, 2000. (Unfunded study).
Low-molecular-weight heparins (LMWH) have been shown to be safe, effective and economically attractive for the outpatient treatment of deep vein thrombosis (DVT). The Vancouver Hospital and Health Sciences Centre (VHHSC) outpatient DVT program was implemented in June, 1999 to take advantage of this safe, effective and economically attractive therapy. The objective of this study was to: (i) determine if the VHHSC outpatient DVT program is safe and effective; (ii) to assess the economic impact compared to inpatient management and; (iii) to evaluate patient satisfaction with the outpatient program.
Prospective non-comparative clinical trial combined with a pre/post economic assessment and post-intervention patient satisfaction survey.
Emergency Department of a major Canadian tertiary care teaching hospital.
Patients were enrolled in the outpatient program if they had a radiographically-diagnosed DVT by an emergency physician.
Eligible patients returned daily to hospital to receive tinzaparin 175 u/kg sc for a minimum of 5 days and warfarin until INR >2 on two consecutive days at which time they were discharged to the care of their family physician.
Clinical evaluation of efficacy was prospectively evaluated by the incidence of recurrent venous thromboembolic events (RVTE) at 3 and 6 months while safety was determined evaluating bleeding complications and thrombocytopenia. Economic assessment was determined by comparing total costs of therapy for each outpatient determined prospectively, to data collected retrospectively from inpatients treated with unfractionated heparin and warfarin. Patient satisfaction in the outpatient DVT program was established by a 19-question mail-out patient satisfaction survey.
Twenty-five patients were treated in the program for a mean length of treatment of 6 days. No RVTE were identified in patients who had reached 3 and 6 months evaluation post discharge. No patient experienced a major bleeding complication or developed thrombocytopenia while 2 patients experienced a minor bleed (epistaxis & hematuria). Average cost/treatment/inpatient was $2214.99 (CAN) compared to $573.00 (CAN) for outpatient therapy, representing a cost savings of $1641.99 (CAN) for every DVT treated using the outpatient DVT program. Overall, 76% of patient satisfaction surveys were returned and indicated that 90% of patients were very satisfied or satisfied with the outpatient program.
This outpatient DVT program is safe, effective, economically attractive and is well-received by the patients enrolled.
Copyright © 2000 by the Journal of Informed Pharmacotherapy. All rights reserved.